Sruthi Adimadhyam

Dr. Sruthi Adimadhyam

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2018 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
SASruthi Adimadhyam
Sruthi Adimadhyam
TLTodd A. Lee
Todd A. Lee
GCGregory Sampang Calip
Gregory Sampang Calip
DMDaphne E. Smith Marsh
Daphne E. Smith Marsh
BLBrian T. Layden
Brian T. Layden
GSGlen T. Schumock
Glen T. Schumock

7 October 2018 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
SASruthi Adimadhyam
Sruthi Adimadhyam
GSGlen T. Schumock
Glen T. Schumock
GCGregory Sampang Calip
Gregory Sampang Calip
DMDaphne E. Smith Marsh
Daphne E. Smith Marsh
BLBrian T. Layden
Brian T. Layden
TLTodd A. Lee
Todd A. Lee

4 February 2021 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
EEEfe Eworuke
Efe Eworuke
NHNicole Haug
Nicole Haug
MBMarie Bradley
Marie Bradley
ACAustin Cosgrove
Austin Cosgrove
TZTancy Zhang
Tancy Zhang
STSengwee Toh
Sengwee Toh
Background: European studies reported an increased risk of nonmelanoma skin cancer associated with hydrochlorothiazide (HCTZ)-containing products. We examined the risks of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) associated with HCTZ compared with angiotensin-converting enzyme inhibitors (ACEIs) in a US population. Methods: We conducted a retrospective cohort study in the US Food and Drug Administration’s Sentinel System. From the date of HCTZ or ACEI dispensing, patients were followed until a SCC or BCC diagnosis requiring excision or topical chemotherapy treatment on or within 30 days after the diagnosis date or a censoring event. Using Cox proportional hazards regression models, we estimated the hazard ratios (HRs), overall and separately by age, sex, and race. We also examined site- and age-adjusted incidence rate ratios (IRRs) by cumulative HCTZ dose within the matched cohort. Results: Among 5.2 million propensity–score matched HCTZ and ACEI users, the incidence rate (per 1000 person-years) of BCC was 2.78 and 2.82, respectively, and 1.66 and 1.60 for SCC. Overall, there was no difference in risk between HCTZ and ACEIs for BCC (HR = 0.99, 95% confidence interval [CI] = 0.97 to 1.00), but there was an increased risk for SCC (HR = 1.04, 95% CI = 1.02 to 1.06). HCTZ use was associated with higher risks of BCC (HR = 1.09, 95% CI = 1.07 to 1.11) and SCC (HR = 1.15, 95% CI = 1.12 to 1.17) among Caucasians. Cumulative HCTZ dose of 50 000 mg or more was associated with an increased risk of SCC in the overall population (IRR = 1.19, 95% CI = 1.05 to 1.35) and among Caucasians (IRR = 1.27, 95% CI = 1.10 to 1.47). Conclusions: Among Caucasians, we identified small increased risks of BCC and SCC with HCTZ compared with ACEI. Appropriate risk mitigation strategies should be taken while using HCTZ.

24 October 2019 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
SASruthi Adimadhyam
Sruthi Adimadhyam
TLTodd A. Lee
Todd A. Lee
GCGregory Sampang Calip
Gregory Sampang Calip
DMDaphne E. Smith Marsh
Daphne E. Smith Marsh
BLBrian T. Layden
Brian T. Layden
GSGlen T. Schumock
Glen T. Schumock

19 October 2020 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
SASruthi Adimadhyam
Sruthi Adimadhyam
EBErin F. Barreto
Erin F. Barreto
NCNoelle M. Cocoros
Noelle M. Cocoros
STSengwee Toh
Sengwee Toh
JBJeffrey S. Brown
Jeffrey S. Brown
XLXiaojuan Li
Xiaojuan Li
The Sentinel System is a national electronic postmarketing resource established by the US Food and Drug Administration to support assessment of the safety and effectiveness of marketed medical products. It has built a large, multi-institutional, distributed data network that contains comprehensive electronic health data, covering about 700 million person-years of longitudinal observation time nationwide. With its sophisticated infrastructure and a large selection of flexible analytic tools, the Sentinel System permits rapid and secure analyses, while preserving patient privacy and health-system autonomy. The Sentinel System also offers enhanced capabilities, including accessing full-text medical records, supporting randomized clinical trials embedded in healthcare delivery systems, and facilitating effective collection of patient-reported data using mobile devices, among many other research programs. The nephrology research community can use the infrastructure, tools, and data that this national resource offers for evidence generation. This review summarizes the Sentinel System and its ability to rapidly generate high-quality, real-world evidence; discusses the program’s experience in, and potential for, addressing gaps in kidney care; and outlines avenues for conducting research, leveraging this national resource in collaboration with Sentinel investigators.

1 August 2023 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
MLMillie D Long
Millie D Long
LPLauren Parlett
Lauren Parlett
JLJames D Lewis
James D Lewis
KHKevin Haynes
Kevin Haynes
SASruthi Adimadhyam
Sruthi Adimadhyam
MKMichael D Kappelman
Michael D Kappelman
Immunosuppressed individuals are at higher risk for COVID-19 complications, yet data in patients with inflammatory bowel disease (IBD) are limited. We evaluated the risk of COVID-19- severe sequelae by medication utilization in a large cohort of patients with IBD. We conducted a retrospective cohort study utilizing insurance claims data between August 31, 2019, and August 31, 2021.We included IBD patients identified by diagnosis and treatment codes. Use of IBD medications was defined in the 90 days prior to cohort entry. Study outcomes included COVID-19 hospitalization, mechanical ventilation, and inpatient death. Patients were followed until the outcome of interest, outpatient death, disenrollment, or end of study period. Due to the aggregate nature of available data, we were unable to perform multivariate analyses. We included 102 986 patients (48 728 CD, 47 592 UC) with a mean age of 53 years; 55% were female. Overall, 412 (0.4%) patients were hospitalized with COVID-19. The incidence of hospitalization was higher in those on corticosteroids (0.6% vs 0.3%; P < .0001; 13.6 per 1000 person-years; 95% confidence interval [CI], 10.8-16.9) and lower in those receiving anti-tumor necrosis factor α therapy (0.2% vs 0.5%; P < .0001; 3.9 per 1000 person-years; 95% CI, 2.7-5.4). Older age was associated with increased hospitalization with COVID-19. Overall, 71 (0.07%) patients required mechanical ventilation and 52 (0.05%) died at the hospital with COVID-19. The proportion requiring mechanical ventilation (1.9% vs 0.05%; P < .0001; 3.9 per 1000 person-years; 95% CI, 2.5-5.9) was higher among users of corticosteroids. Among patients with IBD, those on corticosteroids had more hospitalizations and mechanical ventilation with COVID-19. Anti-tumor necrosis factor α therapy was associated with a decreased risk of hospitalization. These findings reinforce previous guidance to taper and/or discontinue corticosteroids in IBD.